| Ytd | -41.47% | |
| 1y | -48.13% |
| Open | 0.65 | Prev Close | 0.65 | Low | 0.62 | High | 0.69 | Mkt Cap | 121.83M |
| Vol | 1.95M | Avg Vol | 1.35M | EPS | -0.44 | P/E | N/A | Forward P/E | -1.12 |
| Beta | 1.12 | Short Ratio | 0.80 | Inst. Own | 4.18% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 0.88 | 200-d Avg | 1.08 | 1yr Est | 3.50 |
LUCD News
Gainers Elutia (NASDAQ:ELUT) stock moved upwards by 17.2% to $0.94 during Thursday's after-mark
Gainers Nexalin Technology (NASDAQ:NXL) shares increased by 77.8% to $7.61 during Thursday's re
Gainers IM Cannabis (NASDAQ:IMCC) stock rose 108.5% to $3.63 during Friday's pre-market session
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and ra
Lucid Diagnostics confirmed its first LBM win with Concert, opens up 10M covered lives. Analyst main
Lucid Diagnostics (NASDAQ:LUCD) released second-quarter financial results and hosted an earnings cal
Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.08) per share which missed the anal
Lucid Diagnostics reported Q1 revenue miss. Analyst significant expects revenue growth in 2026/27. R
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and ra
Maxim Group analyst Anthony Vendetti maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and low
Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.07) per share which beat the analys
Lucid Diagnostics (NASDAQ:LUCD) reported quarterly sales of $1.256 million which missed the analyst
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage
Top analysts change outlook on top names, like AA, SSSS, TXN, HQY, LUCD, RPM, PAR, ASRT. Morgan Stan
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and ra
Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.10) per share which met the analyst
PAVmed shares pull back Thursday, possibly retracing recent gains on news its subsidiary, Lucid Diag
PAVmed Inc. (PAVM) surges as its subsidiary Lucid Diagnostics (LUCD) secures a contract with VA for
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage,
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and ra
Lucid Diagnostics Inc. $175,000,000 Common Stock, Preferred Stock, Debt Securities, Warrants and Uni
Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.10) per share which beat the analys
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and ra
BTIG analyst Mark Massaro reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $2.
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage
NEW YORK, Sept. 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the
BTIG analyst Mark Massaro maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the pri
Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $
Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage,
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and ra
Cantor Fitzgerald analyst Ross Osborn reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Overweigh
Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and ra
A Needham analyst predicts that Lucid Diagnostics (NASDAQ: LUCD) will see a surge in testing volumes
Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $